Shares surged as Regeneron posted third-quarter results that crushed Wall Street expectations across the board, but a closer look reveals a one-time financial tailwind that investors need to understand before extrapolating the beat forward.
A Beat So Big It Demands Scrutiny
Regeneron delivered adjusted earnings of $20.07 per share, up 70% year-over-year, on revenue of $5.12 billion, a 36% increase.
Revenue topped consensus by roughly 10.5% and non-GAAP EPS beat by about 21.8% — a gap wide enough to push shares past a new 52-week high. The stock jumped as much as 11.5% to $912.63. But the size of the beat owes heavily to a structural change in how Regeneron books its Sanofi partnership profits.
A Debt Payoff Supercharged the Bottom Line
Full repayment of Regeneron's development balance with Sanofi in the second quarter allowed the company to recognize its entire share of collaboration profits in Q3 for the first time.
That drove a 77% increase in Regeneron's share of Sanofi collaboration profits to $2.6 billion.
As a result, Regeneron's profit share jumped to 38% of Dupixent and Kevzara net sales, up from 29% a year ago. This is now the new baseline — a genuine step-up in economics, but not one that will repeat as a year-over-year booster once it anniversaries in mid-2027.
Dupixent Keeps Defying Gravity, Though a Clock Is Ticking
The blockbuster allergy-and-asthma drug hit record global net sales of $6.5 billion, up 35%, with U.S. sales exceeding $5 billion for the first time.
Therapy penetration in its largest market, atopic dermatitis, remains only around 20% , suggesting room to grow. However, Sanofi faces eventual loss of exclusivity on Dupixent post-2030 , explaining why Regeneron expanded its Sanofi alliance to include four next-generation, long-acting antibodies designed to build on Dupixent's success.
That deal brings $1.0 billion in upfront collaboration revenue in Q4, with up to $7.0 billion in future milestones.
A Deep Pipeline Hedges Future Risk
Regeneron has roughly 50 product candidates in clinical development.
Its cancer drug Libtayo grew 51% to $550 million, while its eye treatment EYLEA HD surged 62% to $699 million.
R&D spending is set to rise by a mid-teens percentage in 2027 , a meaningful investment that could pressure near-term margins but signals management is betting aggressively on the next generation. Wall Street expects full-year EPS to climb to roughly $67 over the next 12 months , implying the stock at $870 trades at about 13 times forward earnings — hardly expensive for a biotech growing this fast, if the collaboration economics hold steady.